Adaptive mutability of colorectal cancers in response to targeted therapies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation may be due to a more potent treatment effect with the combination of divarasib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells30.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [30]
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Cited by
Items 301–400 of 435
Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer
Cisneros, L. H., Vaske, C. J., & Bussey, K. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.932763 · Cited by 4
Zhu, J., Fu, S., Zou, X., Zeng, H., Cui, G., Peng, Y., Tang, D., Zhang, F., Shen, H., Zeng, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202500271 · Cited by 9
Corigliano, M., Bernardo, A. D., Lagomarsino, M. C., & Pompei, S. (2025) · PRX Life · doi:10.1103/mh5v-lcyw · Cited by 5
Self-citationOptimal treatment strategy of cancers with intratumor heterogeneity
Zhang, H., & Lei, J. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022625 · Cited by 5
McKnight, I., Raines, R., White, H., Nosoudi, N., Lee, C., Lee, P. H. U., & Shim, J. W. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283470 · Cited by 4
“Greater lifespans in higher-order metazoans correspond with higher gradual accumulation of cellular damage, thereby leading to decreases in tissue function (cellular senescence) and fitness as an organism ages [12].”
BackgroundGramaça, J., Fernandes, I. G., Trabulo, C., Gonçalves, J., dos Santos, R. G., Baptista, A., & Pina, I. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i1.234 · Cited by 4
“Under the stress applied by both the tumour microenvironment and therapies, these subclones continuously compete for space and resources[15].”
Escalante, P. I., Quiñones, L. A., & Contreras, H. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376638 · Cited by 4
“…led to permanent DNA instability and progressive accumulation of genomic damage in persistent cancer cells, which in return increased the chance of acquiring genetic resistance to these targeted therapies, developing a stress-induced hypermutability phenotype (Russo et al., 2019; Gay et al., 2020).”
BackgroundBainbridge, L. J., & Daigaku, Y. (2024) · Cancer Science · doi:10.1111/cas.16188 · Cited by 5
DNA polymerase κ: Friend or foe?
Sweasy, J. B. (2020) · Science Signaling · doi:10.1126/scisignal.abb2934 · Cited by 4
“(7) reported that pharmacological blockade of BRAF and the growth factor receptor EGFR down-regulates the expression of proteins involved in homologydirected repair (HDR) and mismatch repair (MMR) and up-regulates the expression of polymerases Pol, Pol iota (Pol), and Rev1, although they did not characterize the cel…”
BackgroundLiang, T., Tong, W., Ma, S., & Chang, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1773205 · Cited by 6
“bility of anti-EGFR therapy in combination with ICI therapy in CRC patients.(82)”
MethodDaniels, H. G., Knicely, B. G., Miller, A. K., Thompson, A. M., Plattner, R., & Goellner, E. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.940073 · Cited by 4
“showed that targeting EGFR/BRAF downregulates MMR activity (Russo et al., 2019).”
BackgroundKhodaverdian, V. Y., Sano, T., Maggs, L. R., Tomarchio, G., Dias, A., Clairmont, C., Tran, M., & McVey, M. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011181 · Cited by 3
HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy
Saito, S., Kato, S., Arai, U., En, A., Tsunezumi, J., Mizushima, T., Tateishi, K., & Adachi, N. (2025) · Nature Communications · doi:10.1038/s41467-025-59462-2 · Cited by 4
“…1,2,15,16 ; additionally, a recent report suggested a signi fi cant decrease in HR and MMR activity in BRAFi/EGFRi-treated colorectal cancers 76 , further highlighting the importance of rapid assessment of DNA repair status of tumors including those that were originally DNA repair-pro fi…”
Gutierrez, C., Vilas, C. K., Wu, C. J., & Al’Khafaji, A. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859032 · Cited by 3
“Further, treatment with EGFR and BRAF inhibitors in colorectal cancers can increase overall mutability and the likelihood of resistance, demonstrating that targeted therapy can transiently enhance evolutionary potential by accelerating genetic diversity (51).”
BackgroundJin, K.-M., Bao, Q., Zhao, T., Wang, H., Huang, L.-F., Wang, K., & Xing, B.-C. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102464 · Cited by 3
Genomic Stress Responses Drive Lymphocyte Evolvability: An Ancient and Ubiquitous Mechanism
Świątczak, B. (2020) · BioEssays · doi:10.1002/bies.202000032 · Cited by 3
Guerrera, L. P., Napolitano, S., Falco, V. D., Giunta, E. F., Vitiello, P. P., Gravina, A. G., Suarato, G., Perrone, A., Napolitano, R., Martinelli, E., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.005 · Cited by 3
A deep profile of gene expression across 18 human cancersPreprint
Qiu, W., Dincer, A. B., Janizek, J. D., Çelik, S., Pittet, M. J., Naxerova, K., & Lee, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.17.585426 · Cited by 3
“Similarly, reduced expression of mismatch repair proteins can increase mutability and microsatellite instability 66 .”
Marois, A. L., Bailey, S. N. L., Hooper, S., Kumar, S., Sparks, H., Alexandrov, Y., Caswell, D. R., Fröhlich, F., Schlegelmilch, K., Valand, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.14.594112 · Cited by 5
Antigenic cancer persister cells survive direct T cell attackPreprint
Wang, M., Mauch, B. E., Williams, A. F., Barazande-Pour, T., Hoffmann, F. A., Harris, S. H., Lathrop, C. P., Turkal, C. E., Yung, B. S., Paw, M. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643359 · Cited by 4
“Unlike drug resistant cells which engage stable mechanisms that avoid drug stress, persister cells leverage stress as demonstrated by recent reports that sublethal stress promotes persister cell formation, 4 mutagenesis 5,6 and regrowth during treatment (Williams A. F. et al., in revision 7 ).”
Spatial immune heterogeneity in a mouse tumor model after immunotherapy
Šmahel, M., Johari, S. D., Šmahelová, J., Pfeiferová, L., & Nunvář, J. (2024) · Cancer Science · doi:10.1111/cas.16421 · Cited by 2
“11 Chemotherapy can also promote the expression of APOBECs, which have been shown to induce mutagenesis and chemoresistance in dif - ferent tumors.”
Theis, S., Senyigit, J., Büchler, B., Diederichsen, K., Kolck, G., Möhler, M., Hasenburg, & Paul, N. W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1588721 · Cited by 2
Bielo, L. B., Napolitano, S., Avallone, A., Pietrantonio, F., Bordonaro, R., Maiello, E., Pisconti, S., Tamburini, E., Lotesoriere, C., Tortora, G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105877 · Cited by 2
Self-citationMa, G., Jia, H., Tian, X., Wang, G., Zhang, X., Mi, Z., Jia, Y., Wang, L., Liang, Z., Li, D., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07705-1 · Cited by 2
“Notably, exogenous interventions, such as drugs targeting glutamine metabolism, can also directly exacerbate ROS stress within tumor cells [24–26].”
Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
Zhang, K.-Y., Zhu, X.-Z., Yan, Y., Ying, X.-H., Zhang, J., & Wang, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02850-x · Cited by 6
“252 Chemotherapy: Chemotherapy remains a cornerstone of cancer treatment and the only systemic treatment for certain cancer subtypes associated with poor clinicopathologic features.”
Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma
Yang, X., Ma, Z., Zhang, Y., Wu, J., Huang, J., Zhao, W., Mo, F., Lin, Z., Xu, Y., Zhou, Z. M., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106211 · Cited by 2
Das, A. D., Gkoutos, G. V., & Acharjee, A. (2024) · Cancer Medicine · doi:10.1002/cam4.6945 · Cited by 3
“45 When a cell line was treated with cetuximab, 14 western blots showed increased levels of TLS polymerases.”
BackgroundMethodInfluentialThe Potential Links between lncRNAs and Drug Tolerance in Lung Adenocarcinoma
Davis, W. J. H., Drummond, C. J., Diermeier, S. D., & Reid, G. (2024) · Genes · doi:10.3390/genes15070906 · Cited by 4
Iida, N., Imai, M., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1023 · Cited by 2
“Second, anti-EGFR antibodies have been shown to downregulate mismatch repair and activate mutagenesis, which may contribute to the higher frequency of EGFR mutations observed during anti-EGFR therapy (28).”
BackgroundWong, W., Ren, Y., & Leung, F. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13937-6.00007-x · Cited by 2
Cell plasticity and genomic instability in cancer evolution
Xu, Y. K., Li, H., Yang, F., Yang, D., & Zhou, B. S. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00023-w · Cited by 3
Sclafani, F., Fontana, E., Wyrwicz, L. S., Wagner, D., Valle, J. W., Smyth, E. C., Peeters, M., Obermannova, R. L., Neuzillet, C., Lutz, M. P., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.04.001 · Cited by 4
Mutation Rate Evolution Drives Immune Escape In Mismatch Repair-Deficient CancerPreprint
Kayhanian, H., Barmpoutis, P., Lakatos, E., Cross, W. C. H., Caravagna, G., Zapata, L., Litchfield, K., Steele, C. D., Waddingham, W., Patel, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.06.482973 · Cited by 2
Aberrant Signaling Pathways in Cancer
Grumolato, L., & Aaronson, S. A. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm010.pub2 · Cited by 3
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Crisafulli, G., & Siravegna, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260158 · Cited by 2
“This adaptive response allows the tumour to evade the effect of the targeted therapy and continue proliferating, ultimately leading to treatment failure (18, 19, 21).”
BackgroundSelf-citationTúrós, D., Decollogny, M., Moyseos, A., Chanfon, A., Siffert, M., Bousmar, J., Romanens, L., Tille, J., Trédan, O., Labidi‐Galy, S. I., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74125-6 · Cited by 2
“The same procedure was applied to calculate SASP 50 , adaptive mutability gene sets 52 .”
Identifying active and inhibitor-resistant MGMT variants for gene therapy
Cheong, A. W. Y., Fisher, A., Bashyam, A., Forget, A. L., Peters, R., & Nagel, Z. D. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.04.014 · Cited by 1
Self-citationLee, H. M., Zheng, Z., Sorokin, A. V., Wong, C. W., Napolitano, S., Chowdhury, S., Marie, P. K., Singh, A. K., Kochat, V., Bristow, C. A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4370 · Cited by 4
Fabbri, L., Lagadec, L., Guérin, E., Lecourt, H., Baïlle, D., Besse, L., Messaoudi, C., Désaubry, L., Hamdan, H. A., Roy, S., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00479-5 · Cited by 2
“Such adaptive mutability has been shown to be threatened by accumulating DNA double-strand breaks (DSBs), even upon exposure to nongenotoxic therapies (Ali et al, 2022; Cipponi et al, 2020; Russo et al, 2024; Russo et al, 2019).”
InfluentialJaber, T., & Balatif, O. (2025) · International Journal of Dynamics and Control · doi:10.1007/s40435-025-01862-9 · Cited by 1
“For example, resistant cancer cells can remove chemotherapy drugs using special proteins, and targeted treatments like EGFR inhibitors often face rapid adaptive resistance through parallel signaling activation [6].”
Yang, C., Shang, Y., Li, X., Li, J., Li, H., & Han, J. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2598478 · Cited by 2
Bai, H., Zhang, J., Li, Y., Zhang, W., Zhao, Z., Tang, J., Xu, W., & Xiao, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s566889 · Cited by 1
“27 Importantly, CDs can penetrate the cell membrane and enter the cells to enhance the killing power against tumor cells by releasing reactive oxygen species (ROS) in coordination with radiation.”
Rabani, F., Samadi, M. H., Sadeghpour, S., Barashki, S., Aryana, K., Torghabeh, A. E., Soltani, S., Soltani, E., & Aghaee, A. (2026) · BMC Cancer · doi:10.1186/s12885-026-16270-1 · Cited by 1
“In tumors that have been heavily pre-treated but have survived, resistant cell clones emerge, making future therapies more difficult and less effective [17, 18].”
Wang, X., Zhang, C. X., Zhao, Y., He, J., & Thiery, J. P. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10368-5 · Cited by 2
“Collectively, these studies demonstrate that EMT enhances plasticity and stemness, enabling persister cells to survive therapeutic pressure, reconstruct intratumoral heterogeneity, and sustain therapy resistance [93, 94].”
Exploiting DNA damage tolerance for precision oncology
Bhat, A., Lahane, G. P., PANDITA, R. K., Bacolla, A., Hoden, B., Ramos, K. S., Krishnan, S., Sarkar, P. S., Dhar, A., Tainer, J. A., et al. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.08.003 · Cited by 1
Mitotic bypass and continued endocycling promote cancer cell survival after genotoxic chemotherapy
Truskowski, K., Rolle, L. T. A., Wang, B., Butler, G., Yang, M. E., Pienta, K. J., & Amend, S. R. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09305-9 · Cited by 2
Molecular Determinants of Gastrointestinal Cancers
Battaglin, F., Randon, G., Raimondi, A., Pagani, F., Arai, H., Pietrantonio, F., & Lenz, H. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.026 · Cited by 1
The Role of the Microenvironment in Tumor Promoting Stress Responses
Dillekås, H., Schuster, C., Davidsen, K. T., & Straume, O. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_31 · Cited by 1
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
Chen, P., Fang, Q., Chen, D., & Chen, H. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i7.498 · Cited by 1
Metabolism and Multicellularity Revisited
Blackstone, N. W. (2022) · Springer eBooks · doi:10.1007/978-3-031-06059-5_10 · Cited by 1
A genome-wide atlas of recurrent repeat expansions in human cancerPreprint
Erwin, G. S., Gürsoy, G., Al-Abri, R., Suriyaprakash, A., Dolzhenko, E., Zhu, K., Hoerner, C. R., White, S. M., Ramirez, L., Vadlakonda, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.24.505159 · Cited by 1
Intestinal Performance upon Broiler Chickens fed with or without Epidermal Growth FactorPreprint
Shan, C., Liu, Q., Li, J., Liu, E., Tian, J., Liu, Y., Yu, H., & Guotuo, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1950781/v1 · Cited by 1
Advances in fundamental oncology: Year 2019 update
Имянитов, Е. Н. (2020) · Practical oncology · doi:10.31917/2101001
Novel challenges require new solutions
Nicoletti, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818706-7.00003-6
Drug-induced colorectal cancer persister cells show increased mutation ratePreprint
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Bertotti, A., Gherardi, M., Nicolantonio, F. D., Bardelli, A., & Lagomarsino, M. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.17.444478 · Cited by 2
Self-citationZhang, Y., Liang, S., Xiao, B., Hu, J., Pang, Y., Liu, Y., Yang, J., Ao, J., Wei, L., & Luo, X. (2021) · Research Square · doi:10.21203/rs.3.rs-571141/v1
Molecular genetic testing in colon cancer: clinical aspects
Martianov, A. S., Kuligina, E. S., Romanko, A. A., & Имянитов, Е. Н. (2022) · Almanac of Clinical Medicine · doi:10.18786/072-0505-2022-50-002 · Cited by 2
Chemoresistance and metastasis in colorectal cancer
Wong, S. Q. R. (2022) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/155418
Pan-Cancer Analysis Identifies YTHDF2 as an Immunological and Prognostic BiomarkerPreprint
weiwei, L., Liu, C., Chen, Z., Qian, C., Lin, W., Zhao, L., & Zhou, R. (2022) · Research Square · doi:10.21203/rs.3.rs-1516046/v1
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00004-5
Immune infiltration of MMP14 in Pan-cancer and its prognostic effect on tumorPreprint
Li, M., Li, S., Zhou, L., Yang, L., Wu, X., Tang, B., Xie, S., Fang, L., Zheng, S., & Hong, T. (2021) · Research Square · doi:10.21203/rs.3.rs-555119/v1
Mutation of mutator genes marks immunotherapy efficacyPreprint
Chen, K., Wang, X., Zhao, D., Li, Y., Yu, Y., Ira, G., & Zhang, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1541499/v1
CXCL13 Modulates Immunoactive Tumor Microenvironment and Improves Prognosis in Colorectal CancerPreprint
Guo, F., Chen, W., Yan, Y., Cui, Y., Peng, Y., Fang, J., Xuan, B., Hong, J., & Chen, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195922
Ciardiello, F., Troiani, T., Napolitano, S., Falco, V. D., Martini, G., Ciardiello, D., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2187013/v1
Reversible Drug Resistance Mechanisms in Non-small Cell Lung Cancer
Haga, Y. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.22-00133
Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells
Roerden, M., & Lengerke, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_40-1 · Cited by 1
Data from Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Haga, Y., Marrocco, I., Noronha, A., Uribe, M. L., Nataraj, N. B., Sekar, A., Garcia, D. D., Borgoni, S., Lindzen, M., Giri, S., et al. (2023) · doi:10.1158/0008-5472.c.6513052.v1
Data from Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Haga, Y., Marrocco, I., Noronha, A., Uribe, M. L., Nataraj, N. B., Sekar, A., Garcia, D. D., Borgoni, S., Lindzen, M., Giri, S., et al. (2023) · doi:10.1158/0008-5472.c.6513052
Noronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2023) · doi:10.1158/2159-8290.c.6549711.v1
Noronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2023) · doi:10.1158/2159-8290.c.6549711
Magnani, L., Ivanoiu, D., Rosano, D., Slaven, N., Sofyalı, E., Barozzi, I., James, C. T., Cresswell, G. D., Corleone, G., Dhiman, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3443614/v1
Ma, X., Yang, F., Ma, K., Shen, H., Han, J., Wang, K., Yang, Y., Zhu, J., An, R., Wang, Q., et al. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250241
Life, the genome and everything
Rosenberg, S. M. (2023) · Journal of Bacteriology · doi:10.1128/jb.00272-23
Guo, F., Chen, W., Yan, Y., Yao, C., Zhang, R., Shen, C., Cui, Y., Peng, Y., Hong, J., Chen, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3667400/v1
Gut bacteria train tumours to resist therapies
Paterlini, M. (2024) · Nature Italy · doi:10.1038/d43978-024-00021-6
Come i batteri intestinali allenano i tumori a resistere alle terapie.
Paterlini, M. (2024) · Nature Italy · doi:10.1038/d43978-024-00022-5
Drivers of Spatial Immune Heterogeneity in a Mouse Tumor Model after ImmunotherapyPreprint
Šmahel, M., Johari, S. D., Šmahelová, J., Pfeiferová, L., & Nunvář, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855460
Immunotherapeutic strategies for the treatment of colorectal cancer
Parisi, A., Arrichiello, G., Salati, M., & Petrillo, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00003-4
Lim, Z.-F. (2024) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.12594 · Cited by 1
O PAPEL DA DIVERSIDADE DE TLS DNA POLIMERASES HUMANAS PARA O DESENVOLVIMENTO DE NEOPLASIAS
da Silva, B. D. L. B., Rodrigues, A. S. D. N., & Lima, L. S. (2024) · Journal of Education Science and Health · doi:10.52832/jesh.v4i4.471
Che, J., Wang, Q., He, J., Zhang, Z., Chung, J. M., Gallagher, D. N., Hong, X., Rao, H., Shim, E., Haber, J. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.14.632785
Pretzsch, E., Peschel, C., Rokavec, M., Torlot, L., Li, P., Hermeking, H., Werner, J., Klauschen, F., Neumann, J. H. L., Jung, A., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104107 · Cited by 1
“6,10 Nevertheless, recent studies also imply an important role of expression changes rather than genomic alterations induced by fi rst-line treatment of mCRC. 7 A few studies recently identi fi ed gene signatures on a transcriptomic level that predict prognosis 11,12 as well as response to…”
SAEG: A Novel Deep Learning Architecture for Somatic AlterationsPreprint
Iglesias-Martinez, L. F., Wester, D. Y., & Kölch, W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.21.639424
Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case
Marsicano, R. M., Bielo, L. B., Guerini‐Rocco, E., Lombardi, M., Bertani, E., Bassi, F. M., Curigliano, G., Ciardiello, D., Fazio, N., & Zampino, M. G. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.03.003
Ratcliffe, C. D. H., Sparks, H., Boezio, G. L. M., Alexandrov, Y., Jenkins, R. P., Marois, A. L., Soro-Barrio, P., Moughari, F. A., Hulme, H., Lee, R. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658331 · Cited by 2
DFFB suppresses interferon to enable cancer persister cell regrowthPreprint
Williams, A. F., Gervasio, D. A. G., Turkal, C. E., Stuhlfire, A. E., Wang, M., Mauch, B. E., Plawat, R., Nguyen, A. H., Paw, M. H., Hairani, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.670603
Graves, L. A., Subbalakshmi, A. R., Eward, W. C., Jolly, M. K., & Somarelli, J. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192867636.003.0006
Modelling phenotypic heterogeneity and cell-state transitions during cancer progression
Gopalan, V., Goyal, S., & Rehman, S. K. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192867636.003.0010
Intra-tumor Cell Heterogeneity: Different Immune Responses for Different Cells
Roerden, M., & Lengerke, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_40
Giri, S., Selvadurai, B.-R., Nieves, A. S., Gupta, N., Lindzen, M., Chatterjee, R., Genna, A., Daele, M. V., Ramesh-Kumar, D., Zerbib, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.681972
Clinical implications of whole genome sequencing in metastatic colorectal cancer
Smabers, L. P., Nienhuis, H. H., de Leng, W. W. J., Roepman, P., Ciftcibasi, I. Ö. A., Wensink, G. E., Huismans, M. A., Iersel, L. V., Cirkel, G. A., Gootjes, E. C., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03618-3
Huang, A. H., Lee, G. Y., Lu, C. A., Şahin, İ. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00646 · Cited by 4
Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D’Uva, G., & Lauriola, M. (2022) · Figshare · doi:10.6084/m9.figshare.19297937
Trigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713888
Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D’Uva, G., & Lauriola, M. (2022) · Figshare · doi:10.6084/m9.figshare.19297931
Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D’Uva, G., & Lauriola, M. (2022) · Figshare · doi:10.6084/m9.figshare.19297928
Mariotto, E., Rampazzo, E., Bortolozzi, R., Rruga, F., Zeni, I., Manfreda, L., Marchioro, C., Canton, M., Cani, A., Magni, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26641765
Mariotto, E., Rampazzo, E., Bortolozzi, R., Rruga, F., Zeni, I., Manfreda, L., Marchioro, C., Canton, M., Cani, A., Magni, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26641774
Mariotto, E., Rampazzo, E., Bortolozzi, R., Rruga, F., Zeni, I., Manfreda, L., Marchioro, C., Canton, M., Cani, A., Magni, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26641771
Mariotto, E., Rampazzo, E., Bortolozzi, R., Rruga, F., Zeni, I., Manfreda, L., Marchioro, C., Canton, M., Cani, A., Magni, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26641768
Metadata
- Authors
- Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., Sarotto, I., Nagel, Z. D., Piett, C. G., Amatu, A., Sartore-Bianchi, A., Siena, S., Bertotti, A., Trusolino, L., Corigliano, M., Gherardi, M., Lagomarsino, M. C., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- Harvard University (US)
- University of Milan (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Candiolo Cancer Institute, FPO–IRCCS, Candiolo (TO) 10060, Italy.
- Corresponding author
- Russo, Mariangela
- Bardelli, Alberto
- ORCID
- Russo, Mariangela
- Crisafulli, Giovanni
- Sogari, Alberto
- Reilly, Nicole M.
- Arena, Sabrina
- Lamba, Simona
- Bartolini, Alice
- Amodio, Vito
- Magrì, Alessandro
- Novara, Luca
- Sarotto, Ivana
- Nagel, Zachary D.
- Piett, Cortt G.
- Amatu, Alessio
- Sartore-Bianchi, Andrea
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Corigliano, Mattia
- Gherardi, Marco
- Lagomarsino, Marco Cosentino
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Science
- Published
- 2019-12-20
- Volume
- 366
- Issue
- 6472
- Pages
- 1473-1480
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2987148655
- Cited by
- 433
- References
- 62
- Citations by year
- 2026: 41 · 2025: 55 · 2024: 60 · 2023: 70 · 2022: 76 · 2021: 72 · 2020: 57 · 2019: 2
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- H2020 Health (635342-2 MoTriColor, no. 754923 COLOSSUS)
- Ministero della Salute (Ricerca Corrente 2019 RC2019)
- Associazione Italiana per la Ricerca sul Cancro (9970 Extension program, IG. 16788, ID. 21091, ID.21091, AIRC IG 2018 - ID. 21923)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, drug resistance, targeted therapy, EGFR inhibition, BRAF inhibition, DNA mismatch repair, homologous recombination, error-prone DNA polymerases, microsatellite instability, drug-tolerant persister cells, DNA damage, patient-derived xenografts
- MeSH terms
- Adaptation, Biological, Humans, Selection, Genetic, Colorectal Neoplasms, Down-Regulation, Mutagenesis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.